AnaptysBio, Inc. manages royalty-focused financial collaborations tied to Jemperli with GSK and imsidolimab with Vanda. Following the completed separation of First Tracks Biotherapeutics, the company’s recurring updates center on royalty asset management, collaboration economics, contractual rights, stock repurchase activity, and governance changes.
News about ANAB also includes developments involving imsidolimab, a licensed antibody asset being developed by Vanda, and legal or contractual matters related to the Jemperli collaboration. Company announcements have additionally covered board and finance leadership appointments and the corporate transition from a biopharma operations business to a streamlined royalty management model.
Anaptys (ANAB) reported second quarter and transitional fiscal year 2026 results, highlighting higher collaboration revenue, strong Jemperli sales growth at partner GSK, and a large tax-driven profit in continuing operations.
GSK recorded Jemperli global net sales of $331 million for Q2 2026 (up 26% year over year) and $644 million for the first half of 2026 (up 34%). Collaboration revenue at Anaptys rose to $27.5 million for Q2 and $53.0 million for the first half, versus $22.3 million and $50.0 million a year earlier. A $181.5 million income tax benefit, mainly from releasing a valuation allowance on deferred tax assets, drove income from continuing operations to $177.3 million for Q2 and $176.4 million for the first half.
Cash, cash equivalents and investments were $164.1 million at June 30, 2026. The company noted positive interim AZUR-1 data for Jemperli and FDA PDUFA dates for Jemperli in neoadjuvant rectal cancer (February 2027) and Quimilza in GPP (December 12, 2026).
Anaptys (Nasdaq: ANAB) announced that chief financial officer Chris Murphy will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026, at 3:30 p.m. ET. A live webcast and at least 30-day replay will be accessible via the investor section of Anaptys’ website.
Anaptys (Nasdaq: ANAB) reported Q1 2026 results and completed the spin-off of First Tracks Bio, becoming a royalty-focused company managing collaborations for Jemperli with GSK and imsidolimab with Vanda.
Q1 collaboration revenue was $25.6M, cash was $286.5M, and net loss was $52.9M. Jemperli royalties rose 44% to $24.7M. The company announced a $100M stock repurchase plan, a Dec. 12, 2026 PDUFA date for imsidolimab, and key leadership additions.
Anaptys (Nasdaq: ANAB) appointed Christopher M. Murphy as chief financial officer and Owen Hughes to its board of directors, effective May 11, 2026.
Murphy brings investment banking, corporate strategy and biotech CFO experience, while Hughes adds deep royalty management, corporate development and investment management expertise.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 1:30pm ET. Registration is available via the conference website.
Vanda Pharmaceuticals (ANAB) announced publication of a peer‑reviewed NEJM Evidence article reporting the pivotal phase III study of imsidolimab for Generalized Pustular Psoriasis (GPP).
The study findings are included in a Biologics License Application (BLA) for imsidolimab submitted to the U.S. FDA, with a target action date of December 12, 2026.
Summary not available.
Anaptys (Nasdaq: ANAB) completed the taxable spin-off of First Tracks Biotherapeutics (trading as TRAX) on April 20, 2026, distributing one First Tracks share per Anaptys share held as of the April 6, 2026 record date. Anaptys now exclusively manages royalties for Jemperli (with GSK) and imsidolimab (with Vanda).
The company says it will operate a virtual model with limited FTEs, minimal operating expenses, approximately $140–$145 million in net cash at launch, and a projected >95% EBIT margin, aiming to protect and return royalty value to shareholders.
First Tracks Biotherapeutics (Nasdaq: ANAB) secured commitments of $145 million in a private placement, including $80 million in gross proceeds to the company from sale of 5,791,478 primary shares at $13.81 per share. First Tracks Bio is expected to spin off on April 20, 2026 and to launch with $180 million in cash, providing an estimated two-year cash runway. Proceeds will fund general corporate purposes, including clinical development of ANB033. The financing involves institutional investors and placement agents Leerink, Barclays and UBS.
Anaptys (Nasdaq: ANAB) announced the approved spin-off of First Tracks Biotherapeutics (TRAX), expected to begin regular trading on April 20, 2026. Anaptys stockholders will receive one share of TRAX per one share of ANAB (record date April 6, 2026). First Tracks launches with $180 million in cash (including an $80 million private placement) and an initial two-year cash runway to advance three lead clinical programs.